<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="215776">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00276380</url>
  </required_header>
  <id_info>
    <org_study_id>A-38-00240-704</org_study_id>
    <nct_id>NCT00276380</nct_id>
  </id_info>
  <brief_title>A Study on the Use of Tanakan速 for Recovery of Neurological Impairment Following Ischaemic Stroke</brief_title>
  <official_title>A Phase III, Multicentre, Randomised, Double-blinded, Parallel Group, Placebo Controlled Clinical Study for Evaluating the Efficacy of EGb 761速 (Tanakan速) (240mg) in the Recovery of Neurological Impairment Following Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of Tanakan速 240mg in association
      with Acetylsalicylic acid (325mg/day) in the recovery of neurological impairment following
      ischemic stroke.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients with Modified Rankin score 0 or 1 or 2 at the end of study period.</measure>
    <time_frame>Month 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of the following scores and scales: Barthel index, Modified Rankin score, National Institutes of Health Score Scale, Sandoz Scale, Mini Mental State</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Stroke, Acute</condition>
  <condition>Neurological Impairment</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGb761 (Tanakan) and acetylsalicylic acid</intervention_name>
    <description>EGb761 (Tanakan) 40mg tablets (2 tablets tid) 240mg/day AND acetylsalicylic acid (1 tablet once daily), 325 mg/day, for 6 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo and acetylsalicylic acid</intervention_name>
    <description>Placebo 40 mg tablets (2 tablets tid) AND acetylsalicylic acid, 325 mg/day (1 tablet once daily) for 6 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient having had a single infarct in the carotid artery territory 3 to 8 days
             before inclusion

          -  Patient with a moderately severe or severe disability (Modified Rankin Score 4 or 5)

          -  Patient having a Quick's Test (for INR) and APPT (activated partial prothrombin time)
             test in the normal values of the laboratory

        Exclusion Criteria:

          -  Patients having had an ischemic stroke (CT confirmed) less than 3 days and more than
             8 days prior

          -  Patient with known pre-existent cerebral infarction

          -  Infarct damaged area bigger than 1/3 hemisphere

          -  Patient having a score below the cut-off point at Frenchay Aphasia Short Test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Lempereur, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine in Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Faculty Hospital</name>
      <address>
        <city>Prague 2</city>
        <zip>120 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department and Clinic of Neurology of the Old Age</name>
      <address>
        <city>Katowice</city>
        <zip>40 752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMUJ Krakov</name>
      <address>
        <city>Krakov</city>
        <zip>31503</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Postgraduate Medical Teaching Center</name>
      <address>
        <city>Warsaw</city>
        <zip>00 416</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institul de Boli Cerebro Vascular</name>
      <address>
        <city>Bucharest</city>
        <zip>75622</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Universitar de Urgenta</name>
      <address>
        <city>Bucharest</city>
        <zip>Sector 5</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian State Medical University - Neurology and Neurosurgery Clinic</name>
      <address>
        <city>Moscow</city>
        <zip>117415</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian State Medical University - Dept Fundamental Neurology &amp; Neurosurgery</name>
      <address>
        <city>Moscow</city>
        <zip>129327</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ural State Medical Academy</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 17, 2017</lastchanged_date>
  <firstreceived_date>January 12, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Neurologic Manifestations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
